Gemphire Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch GEMP and buy or sell other stocks, ETFs, and their options commission-free!About GEMP
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand.
CEOSteve Gullans, PhD
CEOSteve Gullans, PhD
Employees9
Employees9
HeadquartersLivonia, Michigan
HeadquartersLivonia, Michigan
Founded2014
Founded2014
Employees9
Employees9
GEMP Key Statistics
Market cap18.01M
Market cap18.01M
Price-Earnings ratio-0.58
Price-Earnings ratio-0.58
Dividend yield—
Dividend yield—
Average volume332.98K
Average volume332.98K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$30.25
52 Week high$30.25
52 Week low$6.05
52 Week low$6.05
Stock Snapshot
Gemphire Therapeutics(GEMP) stock is priced at $8.18, giving the company a market capitalization of 18.01M. It carries a P/E multiple of -0.58.
On 2025-12-22, Gemphire Therapeutics(GEMP) stock opened at —, reached a high of —, and a low of —.
The Gemphire Therapeutics(GEMP)'s current trading volume is 0, compared to an average daily volume of 332.98K.
During the past year, Gemphire Therapeutics(GEMP) stock moved between $6.05 at its lowest and $30.25 at its peak.
During the past year, Gemphire Therapeutics(GEMP) stock moved between $6.05 at its lowest and $30.25 at its peak.